PubMed · 1999 · 288 citations · 14 references
MedicineMolecular BiologyOncologyChemotherapyDna RepairMolecular OncologyChemotherapy ResistanceDna DamageDna Double-strand Break RepairDouble-strand Break RepairNucleotide Excision RepairMolecular Drug ResistancePlatinum CompoundsPlatinum SensitivityPlatinum-based AgentsSensitivity
Tumors exhibit a spectrum of cellular responses to chemotherapy ranging from extreme sensitivity to resistance, either intrinsic or acquired. These variable responses are both patient and tumor specific. For platinum DNA-damaging agents, drug resistance depends on the carrier ligand of the platinum complex and is due to a combination of mechanisms including DNA repair. Nucleotide excision repair is the only known mechanism by which bulky adducts, including those generated by platinum chemotherapeutic agents, are removed from DNA in human cells. In this report, we show that the types of DNA lesions generated by three platinum drugs, cisplatin, oxaliplatin, and (Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216), are repaired in vitro with similar kinetics by the mammalian nucleotide excision repair pathway.
14
The Metabolic Basis of Inherited Disease.
Annals of Internal Medicine · 1988 · 7.8K citations
The role of DNA mismatch repair in platinum drug resistance.
Daniel Fink, S Nebel, Stefan Aebi et al. · PubMed · 1996 · 603 citations
Jiaoyan Huang, D L Svoboda, Joyce T. Reardon et al. · Proceedings of the National Academy of Sciences · 1992 · 434 citations
Jiaoyan Huang, Deborah B. Zamble, Joyce T. Reardon et al. · Proceedings of the National Academy of Sciences · 1994 · 349 citations